Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: idos who wrote (10033)	10/31/2008 8:05:57 AM
From: tom pope	Read Replies (1) \| Respond to of 10345

Is there information on PML incidence in the non-MS population, or is it insignificant?

To: idos who wrote (10033)	10/31/2008 9:19:52 AM
From: fred hayes	Read Replies (2) \| Respond to of 10345

Idos, is it reasonable to hope that there will be better risk management as we get more cases? I'm pretty sure only one of the PML's was a "clean" patient. All the others had their immune systems pretty well beat up in advance of T administration. I'm thinking more experience may well lead to better screening of potential patients. Could it turn out that the risk of PML is extremely low in clean patients, resulting in a shift to first line use instead of "rescue" use? I'm also hoping that more experience will generate better treatment, even to the extent that a PML case may not be substantially worse than a few major MS relapses. Am I far off base here? tia fred hayes